LRP11 Inhibitors
Chemical inhibitors of LRP11 target various aspects of cellular function to hinder the protein's activity through distinct mechanisms. GW4869, as an inhibitor of neutral sphingomyelinase (nSMase), can lead to decreased production of ceramide, a lipid that is crucial for vesicular trafficking and membrane composition. This reduction in ceramide levels can result in the functional inhibition of LRP11, as it is involved in these processes. Similarly, Bafilomycin A1 targets the vacuolar-type H+-ATPase (V-ATPase) proton pump, essential for endosomal acidification. Inhibition by Bafilomycin A1 can disrupt the normal trafficking and function of LRP11 by impeding the acidification required for these processes. U18666A, a cholesterol transport inhibitor, can lead to intracellular cholesterol accumulation, which may alter membrane composition and disrupt the proper localization and function of LRP11, which is associated with cholesterol metabolism and trafficking.
Other inhibitors such as PD 98059 and LY294002 target specific kinase pathways. PD 98059 inhibits MEK, which is upstream of ERK in the MAPK/ERK pathway, a signaling cascade that LRP11 interacts with. By preventing the activation of ERK, LRP11's involvement in downstream signaling can be hindered. LY294002 specifically inhibits phosphoinositide 3-kinases (PI3K), which are part of the PI3K/Akt signaling pathway. The inhibition of PI3K can reduce the phosphorylation and activity of Akt, potentially disrupting the processes regulated by LRP11 that depend on this pathway. Furthermore, compounds like Rapamycin inhibit mTOR, which is part of the mTOR signaling pathway that LRP11 has been implicated in. Inhibition of mTOR by Rapamycin can lead to functional inhibition of LRP11 due to the disruption of this signaling pathway. Each of these chemicals, by targeting different molecular pathways and processes, can influence the function of LRP11 within the cell.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GW4869 | 6823-69-4 | sc-218578 sc-218578A | 5 mg 25 mg | $199.00 $599.00 | 24 | |
GW4869 is an inhibitor of neutral sphingomyelinase (nSMase), an enzyme that produces ceramide from sphingomyelin. LRP11 is known to be involved in lipid regulation and vesicle formation, and ceramide is a bioactive lipid involved in these processes. Inhibition of nSMase by GW4869 can lead to reduced ceramide levels, which may disrupt vesicular trafficking or lipid composition of membranes, functionally inhibiting LRP11. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is an inhibitor of mitogen-activated protein kinase kinase (MEK), which is upstream of extracellular signal-regulated kinase (ERK) in the MAPK/ERK pathway. LRP11 interacts with components of the MAPK/ERK pathway, influencing cellular signaling. By inhibiting MEK, PD 98059 can prevent the activation of ERK, functionally inhibiting downstream effects involving LRP11. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3K). LRP11 has been implicated in PI3K/Akt signaling. Inhibition of PI3K by LY294002 can reduce Akt phosphorylation and activity, potentially disrupting processes regulated by LRP11 that depend on PI3K/Akt signaling. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $96.00 $250.00 $750.00 $1428.00 | 280 | |
Bafilomycin A1 is a specific inhibitor of the vacuolar-type H+-ATPase (V-ATPase) proton pump. LRP11 is known to be involved in endosomal trafficking. Inhibition of V-ATPase by Bafilomycin A1 can disrupt endosomal acidification, which is essential for the normal trafficking and function of LRP11. | ||||||
U 18666A | 3039-71-2 | sc-203306 sc-203306A | 10 mg 50 mg | $140.00 $500.00 | 2 | |
U18666A is a cholesterol transport inhibitor that can induce intracellular cholesterol accumulation. LRP11 is associated with cholesterol metabolism and trafficking. By disrupting cholesterol homeostasis, U18666A can alter membrane composition and potentially inhibit the proper localization and function of LRP11. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein is a tyrosine kinase inhibitor that can inhibit several kinases involved in signal transduction. As LRP11 is involved in signaling pathways, the inhibition of these kinases by Genistein can lead to reduced phosphorylation of proteins that are essential for LRP11's function. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $94.00 $348.00 | 69 | |
Dorsomorphin is an inhibitor of BMP signaling, which works by inhibiting the kinase activity of BMP receptors. LRP11 is involved in the regulation of BMP signaling, and its function can be disrupted by inhibiting the pathway with Dorsomorphin. | ||||||
PF 4708671 | 1255517-76-0 | sc-361288 sc-361288A | 10 mg 50 mg | $175.00 $700.00 | 9 | |
PF-4708671 is a specific inhibitor of the p70S6 kinase (S6K1), an enzyme downstream of the PI3K/Akt/mTOR pathway. Since LRP11 functions in lipid metabolism and may interact with this pathway, inhibiting S6K1 with PF-4708671 can disrupt the signaling required for LRP11's function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. The p38 MAP kinase pathway is involved in cellular stress responses and LRP11 may interact with proteins within this pathway. Inhibition of p38 MAP kinase by SB203580 can therefore disrupt cellular processes that require LRP11 function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor which can disrupt the mTOR signaling pathway. LRP11 has been implicated in cellular processes that are regulated by mTOR signaling. By inhibiting mTOR with Rapamycin, the activity of LRP11 can be functionally inhibited due to disruption of this signaling pathway. | ||||||